check_circleStudy Completed

Magnetic Resonance Imaging, Liver Neoplasms

Bayer Identifier:

90932

ClinicalTrials.gov Identifier:

Not Available

EudraCT Number:

Not Available

EU CT Number:

Not Available
MRI study of Gadovist (1.0 M ) and Magnevist with a single i.v. injection in patients with known or suspected liver lesions

Trial purpose

Please see attached Study Results Summary below.

Key Participants Requirements

Sex

N/A

Age

N/A

Trial summary

Enrollment Goal
572
Trial Dates
July 2001 - August 2002
Phase
Phase 3
Could I Receive a placebo
N/A
Products
Gadavist/Gadovist (Gadobutrol, BAY86-4875)
Accepts Healthy Volunteer
N/A

Primary Outcome

Secondary Outcome

Trial design

Multicenter, randomized, double blind, inter-individually controlled MRI study of Gadovist (1.0 M ) and Magnevist with a single i.v. injection (0.1 mmol/kg BW) in patients with known or suspected liver lesions and with independent blinded read and assessment of the truth standard
Trial Type
Interventional
Intervention Type
N/A
Trial Purpose
N/A
Allocation
N/A
Blinding
N/A
Assignment
N/A
Trial Arms
N/A

Additional Information

Click here and search for drug information provided by the FDA.Click here and search for information on any recalls, market or product safety alerts by the FDA which might have occurred with this product.Click here to find results for studies related to marketed products.